Web-Based Advance Care Planning for Patients With Advanced Cancer
A Web-Based Advance Care Planning Intervention to Reduce Preferences for Aggressive Life-Sustaining Treatments in Patients With Advanced Cancer: A Randomized Controlled Trial
The goal of this clinical trial is to determine whether a web-based advance care planning (ACP) intervention can reduce preferences for aggressive life-sustaining treatments among patients with advanced cancer.
The main questions it aims to answer are:
- Does a web-based ACP intervention reduce preferences for aggressive life-sustaining treatments among patients with advanced cancer?
- Does a web-based ACP intervention support informed medical decision-making regarding future care?
Researchers will compare a web-based ACP intervention plus a Patient Right to Autonomy Act leaflet with a Patient Right to Autonomy Act leaflet alone to determine whether the web-based ACP intervention is more effective in reducing preferences for aggressive life-sustaining treatments.
Participants will:
- Be randomly assigned to either an intervention group or a control group
- Receive either a web-based ACP educational program plus a Patient Right to Autonomy Act leaflet, or a Patient Right to Autonomy Act leaflet alone
- Complete questionnaires at baseline, immediately after the intervention, and one week after the intervention
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Advance care planning (ACP) is a process that enables individuals to understand and communicate their values, goals, and preferences regarding future medical care. ACP is particularly important for patients with advanced cancer, who may face complex decisions regarding life-sustaining treatments and end-of-life care. However, ACP participation remains limited, and innovative approaches are needed to improve patient engagement.
This study was designed to evaluate the effectiveness of a web-based ACP intervention in reducing preferences for aggressive life-sustaining treatments among patients with advanced cancer. The intervention was developed to provide accessible ACP education and information regarding the Patient Right to Autonomy Act in Taiwan.
A single-blind randomized controlled trial design was used. A total of 110 patients with stage III or IV cancer were recruited and randomly assigned to either an intervention group (n = 55) or a control group (n = 55). Participants in the intervention group received a web-based ACP educational program in addition to a Patient Right to Autonomy Act leaflet, whereas participants in the control group received the leaflet alone.
Outcome assessments were conducted at baseline (T1), immediately after the intervention (T2), and one week after the intervention (T3). The primary objective was to determine whether the web-based ACP intervention reduced preferences for aggressive life-sustaining treatments. The study also examined factors associated with treatment preferences and medical decision-making.
The findings of this study may contribute to the development of accessible ACP interventions and support informed decision-making among patients with advanced cancer.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Taipei City
-
Taipei, Taipei City, Taiwán
- Tri-Service General Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Diagnosed with advanced cancer (stage III or IV)
- Aged 18 years or older
- Able to communicate fluently in Mandarin Chinese or Taiwanese
- Able and willing to provide informed consent
- No cognitive impairment
- Have access to Internet-connected electronic devices at home
- Have not previously received advance care planning (ACP) consultation
- Have not completed an advance directive (AD)
Exclusion Criteria:
- No access to Internet-connected electronic devices at home
- Unable to operate Internet-based electronic devices
- Previous participation in ACP consultation or completion of an AD
- Cognitive impairment
- Severe physical or psychological symptoms that would interfere with participation in the study
- Concurrent participation in another intervention study
- Refusal to participate
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Web-Based ACP Intervention Group
Participants received a web-based advance care planning (ACP) educational program in addition to a Patient Right to Autonomy Act leaflet.
|
A web-based educational program designed to improve advance care planning knowledge, promote informed decision-making, and facilitate discussions regarding future medical care among patients with advanced cancer.
An educational leaflet providing information about the Patient Right to Autonomy Act and advance care planning.
|
|
Otro: Control Group
Participants received a Patient Right to Autonomy Act leaflet only.
|
An educational leaflet providing information about the Patient Right to Autonomy Act and advance care planning.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Preference for Aggressive Life-Sustaining Treatments
Periodo de tiempo: Baseline and 1 Week After Intervention
|
Preferences for aggressive life-sustaining treatments were assessed using the Life-Sustaining Treatment Preference Questionnaire.
Higher scores indicate stronger preferences for aggressive life-sustaining treatments.
Changes from baseline were compared between the intervention and control groups.
|
Baseline and 1 Week After Intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Hsueh-Hsing Pan, PhD, National Defense Medical University
- Investigador principal: Yu-Shiue Lin, National Defense Medical University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- TSGHIRB No. A202305148
- TSGH_E_113274 (Otro número de subvención/financiamiento: Tri-Service General Hospital)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .